Bruker (NASDAQ:BRKR) Releases Earnings Results, Beats Estimates By $0.01 EPS

Bruker (NASDAQ:BRKR) posted its earnings results on Thursday. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01, Zacks reports. Bruker had a net margin of 9.41% and a return on equity of 21.52%. Bruker updated its FY 2025 guidance to 2.670-2.720 EPS.

Bruker Stock Down 3.6 %

Shares of BRKR stock traded down $1.85 during trading hours on Thursday, reaching $49.80. 1,244,487 shares of the company’s stock were exchanged, compared to its average volume of 1,545,847. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The stock has a market cap of $7.55 billion, a PE ratio of 23.93, a PEG ratio of 3.81 and a beta of 1.16. The stock’s fifty day moving average price is $57.88 and its two-hundred day moving average price is $60.77.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BRKR. Guggenheim reissued a “buy” rating on shares of Bruker in a research note on Friday, January 17th. Barclays reduced their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday. TD Cowen reduced their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. UBS Group assumed coverage on shares of Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target on the stock. Finally, The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target on the stock in a research note on Thursday, December 5th. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $74.09.

Insider Activity

In related news, CEO Frank H. Laukien acquired 100,000 shares of the stock in a transaction on Monday, November 18th. The shares were bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 28.30% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.